DUBLIN – PDC*line Pharma SAS could earn up to €108 million (US$122.7 million) in up-front and milestone payments from a license and option agreement with LG Chem Ltd. for its cell-based cancer vaccine, PDC*lung, which is in development for non-small-cell lung cancer.